15,214 Shares in AtriCure, Inc. (NASDAQ:ATRC) Bought by Mackenzie Financial Corp

Mackenzie Financial Corp bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,214 shares of the medical device company's stock, valued at approximately $465,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Johnson Financial Group Inc. boosted its holdings in AtriCure by 1,184.1% in the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock valued at $49,000 after purchasing an additional 1,492 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV lifted its holdings in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after acquiring an additional 932 shares during the period. State of Wyoming lifted its holdings in shares of AtriCure by 21.9% during the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after acquiring an additional 446 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of AtriCure by 232.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company's stock worth $88,000 after acquiring an additional 2,008 shares during the period. Institutional investors own 99.11% of the company's stock.

AtriCure Price Performance

ATRC stock traded up $0.07 during trading on Friday, reaching $34.94. 371,162 shares of the company were exchanged, compared to its average volume of 649,456. The company has a 50-day moving average of $32.45 and a two-hundred day moving average of $34.66. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -36.78 and a beta of 1.59. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The firm had revenue of $123.62 million during the quarter, compared to analysts' expectations of $122.92 million. During the same period in the prior year, the company posted ($0.28) EPS. The company's revenue was up 13.5% on a year-over-year basis. As a group, equities analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the company's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total value of $83,600.00. Following the sale, the insider now directly owns 73,550 shares of the company's stock, valued at approximately $2,459,512. This represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 3.50% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ATRC shares. UBS Group cut their price target on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a report on Wednesday, April 30th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Wall Street Zen downgraded shares of AtriCure from a "buy" rating to a "hold" rating in a report on Sunday, June 1st. Finally, Canaccord Genuity Group cut their price target on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $50.67.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.